About Us

Programs and Services

Reimbursement Review

Reimbursement Recommendations

CADTH reviews drugs and makes reimbursement recommendations to Canada's federal, provincial, and territorial public drug programs, with the exception of Quebec, to guide their drug reimbursement decisions.

Provisional Funding Algorithms

CADTH provides advice to the drug programs on the appropriate place in therapy for the drugs within a particular therapeutic area, including the impact of new drugs on the sequencing of treatments for the purposes of reimbursement.

  1. Procedures for CADTH Non-Sponsored Reimbursement Reviews
  2. Procedures for CADTH Streamlined Drug Class Reviews

Health Technology Review

A customized review of a health technology. It may consist of one, or a combination, of the following: an environmental scan, a rapid review, a clinical review, a pharmacoeconomic review, and a review of patient perspectives, and it may also include the legal, ethical, social, implementation, environmental, and policy implications of the health technology. Appropriate use recommendations are provided where applicable.

Read the following process documents for more information about the services included within the Health Technology Review program. Process documents include details on each service, including how topics are identified and how each product is produced.

  1. Environmental Scan Process
  2. Overview of HTA and OU Medical Devices and Clinical Interventions
  3. Rapid Review Process
  4. CADTH Procedures for Implementation Advice for Health Technologies
  5. Procedures for Integrated Technology Reviews for Drugs

Horizon Scan

A high-level summary of a new or emerging health technology likely to have a significant impact on the delivery of health care in Canada.

Read the Horizon Scan process document for more information about the CADTH Horizon Scanning Service, including how topics are identified and how each Horizon Scan product is produced:

Other Programs and Services

Scientific Advice 

Offers pharmaceutical companies advice on their early drug development plans from a health technology assessment perspective.